Gelonghui 10/18 丨China Biotechnology Service (08037.HK) announcement,On October 18, 2023, the Company and AstraZeneca Investment (China) Co., Ltd. (“AstraZeneca (China)”, together with the Company collectively the “Contractor”) entered into a strategic cooperation framework agreement. According to this, the contractor agreed to cooperate on the development of (i) the improvement, commercialization and licensing rights of immunocyte therapy; (ii) the design, planning and ecological construction of R&D and production sites; and (ii) cooperation models with innovative platforms.
AstraZeneca (China) has built a strategic resource area and a healthy innovation ecosystem integrating R&D, production, operation, innovation, capital and talents in China. Shanghai Longyao is a pioneer in developing CD20 targeted autochimeric antigen receptor CAR-T cell therapy to treat B-cell malignanciesOne.
The Board of Directors believes that establishing a strategic partnership with AstraZeneca (China) through a framework agreement and cooperation matters will facilitate the development of the Group's business. In particular, it will resonate with international peers, use Shanghai Longyao's patented technology to develop a new generation of CAR-T to save lives, and bring maximum returns to the company and its shareholders in the long run.